Oncology
Tumors
7
Pipeline Programs↗
20
Active Trials↗
14
Companies Involved↗
Tumors is an early-stage landscape with 7 programs across 14 companies. The most active players are Sanofi, Iovance Biotherapeutics, Inc., Merck & Co..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 1
No programs
Phase 24
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
7programs
Small molecule457%
Monoclonal antibody114%
Protein / enzyme114%
Cell therapy114%
Modality classified for 80% of 10 pipeline programs.
Analysis
Trial Status
66
clinical trials
Completed26 · 39%
Recruiting16 · 24%
Terminated11 · 17%
Withdrawn5 · 8%
Active, not recruiting4 · 6%
Unknown status3 · 5%
Other1 · 2%
Clinical Trials
Trial Activity
66 trials
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
Recruiting·—·Phase 1·NCT06177171·18 enrolled
Lurbinectedin in FET-Fused Tumors
Recruiting·—·Phase 1/2·NCT05918640·63 enrolled
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Recruiting·—·Phase 1/2·NCT05407441·49 enrolled
Single-center, Single-arm Exploratory Clinical Study on the Safety and Efficacy of Human CD5 Chimeric Antigen Receptor T Cell Injection CD5CART in the Treatment of Relapsed and Refractory CD5+ Hematologic Cancer Subjects
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07234110·18 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)